A First-in-human clinical trial of IMC-C103C as monotherapy and in combination with Atezolizumab for solid tumors
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Atezolizumab (Primary) ; IMC C103C (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Immunocore
- 03 Dec 2018 New trial record
- 19 Nov 2018 According to an Immunocore media release, Genentech and Immunocore will co-develop IMC-C103C.
- 19 Nov 2018 According to an Immunocore media release, the company plans to initiate this trial in early 2019.